Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy SAB is comprised of industry and academic leaders in the cell therapy field, covering important areas of expertise including cutting edge research, preclinical development, manufacturing, and clinical development.

Click here to view original post